BNP Paribas Financial Markets Trims Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

BNP Paribas Financial Markets lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 88.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,398 shares of the company’s stock after selling 402,852 shares during the quarter. BNP Paribas Financial Markets’ holdings in Amneal Pharmaceuticals were worth $453,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Profund Advisors LLC raised its holdings in shares of Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after buying an additional 1,680 shares during the period. Rothschild Investment LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $26,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Amneal Pharmaceuticals by 13.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock valued at $222,000 after buying an additional 4,115 shares during the period. Gladius Capital Management LP purchased a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $37,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $42,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

AMRX has been the topic of several research analyst reports. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Piper Sandler upped their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a report on Friday, September 6th. Finally, StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $10.00.

Insider Transactions at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This represents a 76.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $7.83 on Friday. The stock’s 50-day moving average is $8.49 and its two-hundred day moving average is $7.90. Amneal Pharmaceuticals, Inc. has a 1-year low of $4.74 and a 1-year high of $9.48. The company has a market cap of $2.43 billion, a price-to-earnings ratio of -11.51 and a beta of 1.12.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.